Effect of selumetinib on the growth of anastrozole-resistant tumors (Q39178760)

9 September 2017

title

Effect of selumetinib on the growth of anastrozole-resistant tumors (English)

1 reference

9 September 2017

1

1 reference

9 September 2017

Armina Kazi

2

1 reference

9 September 2017

Olga Golubeva

series ordinal

3

1 reference

9 September 2017

Preeti Shah

series ordinal

4

1 reference

9 September 2017

Angela Brodie

series ordinal

5

1 reference

9 September 2017

language of work or name

English

0 references

publication date

19 March 2013

1 reference

Breast Cancer Research and Treatment

9 September 2017

published in

1 reference

9 September 2017

volume

138

1 reference

9 September 2017

issue

3

1 reference

9 September 2017

page(s)

699-708

1 reference

Extended adjuvant endocrine therapy in breast cancer: current status and future directions

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2474-5

Aromatase inhibitors--a triumph of translational oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2474-5

The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal patients: factors influencing the success of patient recruitment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2474-5

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2474-5

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2474-5

Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2474-5

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2474-5

Effects of exemestane and tamoxifen in a postmenopausal breast cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2474-5

Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2474-5

Applicability of the intratumor aromatase preclinical model to predict clinical trial results with endocrine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2474-5

Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2474-5

Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2474-5

Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2474-5

Sensitivity to the aromatase inhibitor letrozole is prolonged after a "break" in treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2474-5

The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2474-5

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2474-5

Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2474-5

Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2474-5

In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2474-5

Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2474-5

Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2474-5

Stopping treatment can reverse acquired resistance to letrozole

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2474-5

Toremifene-atamestane; alone or in combination: predictions from the preclinical intratumoral aromatase model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2474-5

The role of mitogen-activated protein (MAP) kinase in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2474-5

Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2474-5

Adaptive hypersensitivity following long-term estrogen deprivation: involvement of multiple signal pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2474-5

Cross-talk between peptide growth factor and estrogen receptor signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2474-5

Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2474-5

Adaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2474-5

Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2474-5

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2474-5

The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2474-5

Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2474-5

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2474-5

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2474-5

10.1007/S10549-013-2474-5

21 January 2018

Identifiers

DOI

1 reference

9 September 2017

1 reference